Article
Citigroup Maintains Buy on Larimar Therapeutics, Raises Price Target to $14
Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from $12 to $14.
Comments
- No comments yet. Be the first to comment!